

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 December 2009 (30.12.2009)

(10) International Publication Number
WO 2009/156857 A1

(51) International Patent Classification:

C07D 241/52 (2006.01) A61K 31/497 (2006.01)
C07D 401/04 (2006.01) A61P 25/28 (2006.01)

(21) International Application Number:

PCT/IB2009/006445

(22) International Filing Date:

25 June 2009 (25.06.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

08 290 619.9 26 June 2008 (26.06.2008) EP

(71) Applicants (for all designated States except US): **MIT-SUBISHI TANABE PHARMA CORPORATION** [JP/JP]; 2-6-18 Kitahama, Chuo-ku, Osaka-shi, Osaka 541-8505 (JP). **SANOVI-AVENTIS** [FR/FR]; 174 Avenue de France, F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LOCHEAD, Alistair** [FR/FR]; Patent Department c/o Sanofi-aventis, 174 avenue de France, F-75013 Paris (FR). **SAADY, Mourad** [FR/FR]; Patent Department, c/o Sanofi-Aventis, 174 avenue de France, F-75013 Paris (FR). **YAICHE, Philippe** [FR/FR]; c/o Sanofi-Aventis, Département Brevets, 174 avenue de France, F-75013 Paris (FR).

(74) Agent: **DEPRE, Marie-Line**; Sanofi-Aventis, Patent Department, 174 avenue de France, F-75013 Paris (FR).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: SUBSTITUTED N-OXIDE PYRAZINE DERIVATIVES



(57) Abstract: A N-oxide pyrazine derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: (I) wherein: R1 represents a 4-pyridine ring, a halogen atom; R2 represents a hydrogen atom; R3 represents a hydrogen atom; R4 represents: a phenylCi-3alkyl group, this group being optionally substituted; R5 represents a hydrogen atom; in the form of a free base or of an addition salt with an acid. Use in Therapy

WO 2009/156857 A1

SUBSTITUTED N-OXIDE PYRAZINE DERIVATIVES

Technical Field

The present invention relates to compounds that are useful as an active
5 ingredient of a medicament for preventive and/or therapeutic treatment of
neurodegenerative diseases caused by abnormal activity of GSK3 β .

Background Art

10 GSK3 β (glycogen synthase kinase 3 β) is a proline directed serine,
threonine kinase that plays an important role in the control of metabolism,
differentiation and survival. It was initially identified as an enzyme able to
phosphorylate and hence inhibit glycogen synthase. It was later recognized that
15 GSK3 β was identical to tau protein kinase 1 (TPK1), an enzyme that
phosphorylates tau protein in epitopes that are also found to be
hyperphosphorylated in Alzheimer's disease and in several taupathies.

Interestingly, protein kinase B (AKT) phosphorylation of GSK3 β results in a loss of
its kinase activity, and it has been hypothesized that this inhibition may mediate
some of the effects of neurotrophic factors. Moreover, phosphorylation by GSK3 β
20 of β -catenin, a protein involved in cell survival, results in its degradation by an
ubiquitination dependent proteasome pathway.

Thus, it appears that inhibition of GSK3 β activity may result in neurotrophic
activity. Indeed there is evidence that lithium, an uncompetitive inhibitor of GSK3 β ,
enhances neuritogenesis in some models and also increases neuronal survival,
25 through the induction of survival factors such as Bcl-2 and the inhibition of the
expression of proapoptotic factors such as p53 and Bax.

Recent studies have demonstrated that β -amyloid increases the GSK3 β activity
and tau protein phosphorylation. Moreover, this hyperphosphorylation as well as
the neurotoxic effects of β -amyloid are blocked by lithium chloride and by a
30 GSK3 β antisense mRNA. These observations strongly suggest that GSK3 β may
be the link between the two major pathological processes in Alzheimer's disease:
abnormal APP (Amyloid Precursor Protein) processing and tau protein
hyperphosphorylation.

35 Although tau hyperphosphorylation results in a destabilization of the neuronal
cytoskeleton, the pathological consequences of abnormal GSK3 β activity are,
most likely, not only due to a pathological phosphorylation of tau protein because,

as mentioned above, an excessive activity of this kinase may affect survival through the modulation of the expression of apoptotic and antiapoptotic factors. Moreover, it has been shown that β -amyloid-induced increase in GSK3 β activity results in the phosphorylation and, hence the inhibition of pyruvate dehydrogenase, a pivotal enzyme in energy production and acetylcholine synthesis.

Altogether these experimental observations indicate that GSK3 β may find application in the treatment of the neuropathological consequences and the cognitive and attention deficits associated with Alzheimer's disease, as well as other acute and chronic neurodegenerative diseases and other pathologies where GSK3 β is deregulated (Nature reviews Vol.3, June 2004, p.479-487; Trends in Pharmacological Sciences Vol. 25 No. 9, Sept. 2004, p. 471-480; Journal of neurochemistry 2004, 89, 1313-1317; Medicinal Research Reviews, Vol. 22, No. 4, 373-384, 2002).

The neurodegenerative diseases include, in a non-limiting manner, Parkinson's disease, tauopathies (e.g. Fronto temporal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy), Wilson's disease, Huntington's disease (The Journal of biological chemistry Vol. 277, No. 37, Issue of September 13, pp. 33791-33798, 2002), Prion disease (Biochem. J. 372, p.129-136, 2003) and other dementia including vascular dementia; acute stroke and other traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; amyotrophic lateral sclerosis (European Journal of Neuroscience, Vol. 22, pp. 301-309, 2005) peripheral neuropathies; retinopathies and glaucoma. Recent studies have also shown that inhibition of GSK3 β results in neuronal differentiation of embryonic stem cells (ESC) and support the renewal of human and mouse ESCs and the maintenance of their pluripotency. This suggests that inhibitors of GSK3 β could have applications in regenerative medicine (Nature Medicine 10, p. 55 - 63, 2004).

Inhibitors of GSK3 β may also find application in the treatment of other nervous system disorders, such as bipolar disorders (manic-depressive illness). For example lithium has been used for more than 50 years as a mood stabiliser and the primary treatment for bipolar disorder. The therapeutic actions of lithium are observed at doses (1-2 mM) where it is a direct inhibitor of GSK3 β . Although the mechanism of action of lithium is unclear, inhibitors of GSK3 β could be used to mimic the mood stabilising effects of lithium. Alterations in Akt-GSK3 β signaling

have also been implicated in the pathogenesis of schizophrenia.

In addition, inhibition of GSK3 β could be useful in treating cancers, such as colorectal, prostate, breast, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukaemia and several virus-induced tumours. For example, the active form of GSK3 β has been shown to be elevated in the tumors of colorectal cancer patients and inhibition of GSK3 β in colorectal cancer cells activates p53-dependent apoptosis and antagonises tumor growth. Inhibition of GSK3 β also enhances TRAIL-induced apoptosis in prostate cancer cell lines. GSK3 β also plays a role in the dynamics of the mitotic spindle and inhibitors of GSK3 β prevent chromosome movement and lead to a stabilisation of microtubules and a prometaphase-like arrest that is similar to that observed with low doses of Taxol. Other possible applications for GSK3 β inhibitors include therapy for non-insulin dependent diabetes (such as diabetes type II), obesity and alopecia.

Inhibitors of human GSK3 β may also inhibit pfGSK3, an ortholog of this enzyme found in *Plasmodium falciparum*, as a consequence they could be used for the treatment of malaria (Biochimica et Biophysica Acta 1697, 181- 196, 2004).

Recently, both human genetics and animal studies have pointed out the role of Wnt/LPR5 pathway as a major regulator of bone mass accrual. Inhibition of GSK3 β leads to the consequent activation of canonical Wnt signalling. Because deficient Wnt signalling has been implicated in disorders of reduced bone mass, GSK3 β inhibitors may also be used for treating disorders of reduced bone mass, bone-related pathologies, osteoporosis.

According to recent data, GSK3 β inhibitors might be used in the treatment or prevention of *Pemphigus vulgaris*.

Recent studies show that GSK3beta inhibitor treatment improves neutrophil and megakaryocyte recovery. Therefore, GSK3beta inhibitors will be useful for the treatment of neutropenia induced by cancer chemotherapy.

Previous studies have shown that GSK3 activity decreases LTP, a electrophysiological correlate of memory consolidation, suggesting that inhibitor of this enzyme may have procognitive activity. Procognitive effects of the compound could find application for the treatment of memory deficits characteristic of Alzheimer's disease, Parkinson disease, age-associated memory impairment, mild cognitive impairment, brain trauma, schizophrenia and other conditions in which such deficits are observed.

Inhibitors of GSK3 β may also find application in the treatment of parenchymal


renal diseases (Nelson PJ, Kidney International Advance online publication 19 dec 2007) and in the prevention or treatment of muscle atrophy (J. Biol. Chem (283) 2008, 358-366)

5 Disclosure of the Invention

An object of the present invention is to provide compounds useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of a disease caused by abnormal GSK3 β activity, more particularly of neurodegenerative diseases. More specifically, the object is to provide novel
10 compounds useful as an active ingredient of a medicament that enables prevention and/or treatment of neurodegenerative diseases such as Alzheimer's disease.

Thus, the inventors of the present invention have identified compounds
15 possessing inhibitory activity against GSK3 β . As a result, they found that compounds represented by the following formula (I) had the desired activity and were useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of the aforementioned diseases.

20 The present invention thus provides as an object of the invention the N-oxide pyrazine derivatives represented by formula (I) or salts thereof, solvates thereof or hydrates thereof:



25 wherein:

R1 represents a 4-pyridine ring, a halogen atom;

R2 represents a hydrogen atom;

R3 represents a hydrogen atom;

R4 represents:

- a phenylC₁₋₃alkyl group, this group being optionally substituted by 1 to 4 substituents selected from a C₁₋₆ alkyl group, a halogen atom, a C₁₋₂ perhalogenated alkyl group, a C₁₋₃ halogenated alkyl group, a hydroxyl group, a C₁₋₆ alkoxy group, a C₁₋₂ perhalogenated alkoxy group, a C₁₋₆ alkylsulfonyl group, a nitro, a cyano, an amino, a C₁₋₆ monoalkylamino group or a C₂₋₁₂ dialkylamino group, an acetoxy group, an aminosulfonyl group;

R5 represents a hydrogen atom;

in the form of a free base or of an addition salt with an acid.

According to another aspect of the present invention, there is provided a medicament comprising as an active ingredient a substance selected from the group consisting of the N-oxide pyrazine derivatives represented by formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof. As preferred embodiments of the medicament, there are provided the aforementioned medicament which is used for preventive and/or therapeutic treatment of diseases caused by abnormal GSK3 β activity, and the aforementioned medicament which is used for preventive and/or therapeutic treatment of neurodegenerative diseases and in addition other diseases such as: Non-insulin dependent diabetes (such as diabetes type II) and obesity; malaria, bipolar disorders (manic depressive illness); schizophrenia; alopecia or cancers such as colorectal, prostate, breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukaemia, several virus-induced tumours and bone related pathologies; the treatment of parenchymal renal diseases and in the prevention or treatment of muscle atrophy; the treatment of cognitive and memory deficit. The medicament could also find an application in regenerative medicine.

25

As further embodiments of the present invention, there are provided the aforementioned medicament wherein the diseases are neurodegenerative diseases and are selected from the group consisting of Alzheimer's disease, Parkinson's disease, tauopathies (e.g. Frontotemporal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy), Wilson's disease, Huntington's disease, Prion disease and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma;

30

amyotrophic lateral sclerosis; peripheral neuropathies; retinopathies and glaucoma, and the aforementioned medicament in the form of pharmaceutical composition containing the above substance as an active ingredient together with one or more pharmaceutical additives.

- 5 As further embodiments of the present invention, there are provided the aforementioned medicament wherein the bones related pathologies are osteoporosis.

The present invention further provides an inhibitor of GSK3 β activity comprising as an active ingredient a substance selected from the group consisting of the N-oxide pyrazine derivatives of formula (I) and the salts thereof, and the solvates thereof and the hydrates thereof.

According to further aspects of the present invention, there is provided a method for preventive and/or therapeutic treatment of neurodegenerative diseases caused by abnormal GSK3 β activity, which comprises the step of administering to a patient a preventively and/or therapeutically effective amount of a substance selected from the group consisting of N-oxide pyrazine derivatives of formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof; and a use of a substance selected from the group consisting of the N-oxide pyrazine derivatives of formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof for the manufacture of the aforementioned medicament.

As used herein, the C₁₋₆ alkyl group represents a straight or branched or cyclo alkyl group having 1 to 6 carbon atoms, optionally substituted by a straight, branched or cyclic C₁₋₆ alkyl group, for example, methyl group, ethyl group, *n*-propyl group, isopropyl group, *n*-butyl group, isobutyl group, *sec*-butyl group, *tert*-butyl group, *n*-pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group, *n*-hexyl group, isohexyl group, cyclopropylmethyl group and the like.

The C₂₋₁₂ dialkylamino group represents an amino group substituted by two C₁₋₆ alkyl groups, for example, dimethylamino group, ethylmethylamino group, diethylamino group, methylpropylamino group and diisopropylamino group and the like;

The "phenylC₁₋₃alkyl group, this group being optionally substituted"

represent an optional substitution on the alkyl part or the phenyl part of the phenylC₁₋₃alkyl group

5 A leaving group L represents a group which could be easily cleaved and substituted; such a group may be for example a tosyl, a mesyl, a bromide and the like.

The compounds represented by the aforementioned formula (I) may form a salt. Examples of the salt include, when an acidic group exists, salts of alkali metals and alkaline earth metals such as lithium, sodium, potassium, magnesium, and calcium; salts of ammonia and amines such as methylamine, dimethylamine, 10 trimethylamine, dicyclohexylamine, tris(hydroxymethyl)aminomethane, *N,N*-bis(hydroxyethyl)piperazine, 2-amino-2-methyl-1-propanol, ethanolamine, *N*-methylglucamine, and L-glucamine; or salts with basic amino acids such as lysine, δ -hydroxylysine and arginine. The base-addition salts of acidic compounds are prepared by standard procedures well known in the art.

When a basic group exists, examples include salts with mineral acids such as hydrochloric acid, hydrobromic acid; salts with organic acids such as acetic acid, propionic acid, tartaric acid, fumaric acid, maleic acid, malic acid, oxalic acid, 20 succinic acid, citric acid, benzoic acid and the like,.


The acid-addition salts of the basic compounds are prepared by standard procedures well known in the art which include, but are not limited thereto, dissolving the free base in an aqueous alcohol solution containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base 25 and an acid in an organic solvent, in which case the salt separates directly, or is precipitated with a second organic solvent, or can be obtained by concentration of the solution. The acids which can be used to prepare the acid-addition salts include preferably those which produce, when combined with the free base, pharmaceutically-acceptable salts, that is, salts whose anions are relatively 30 innocuous to the animal organism in pharmaceutical doses of the salts, so that the beneficial properties inherent in the free base are not compromised by side effects ascribable to the anions. Although medicinally acceptable salts of the basic compounds are preferred, all acid-addition salts are within the scope of the

present invention.

In addition to the N-oxide pyrazine derivatives represented by the
 5 aforementioned formula (I) and salts thereof, their solvates and hydrates also fall
 within the scope of the present invention.

The N-oxide pyrazine derivatives represented by the aforementioned
 formula (I) may have one or more asymmetric carbon atoms. As for the
 stereochemistry of such asymmetric carbon atoms, they may independently be
 10 either in (R) or (S) configuration, and the derivative may exist as stereoisomers
 such as optical isomers, or diastereoisomers. Any stereoisomers in pure form,
 any mixtures of stereoisomers, racemates and the like fall within the scope of the
 present invention.

In a first embodiment of the invention, there is provided compounds



15

wherein:

R1 represents a 4-pyridine ring, a halogen atom;

R2 represents a hydrogen atom;

20 R3 represents a hydrogen atom;

R4 represents: a phenylC₁₋₃alkyl group, this group being optionally substituted by
 1 to 4 substituents selected from a halogen atom, a hydroxyl group;

R5 represents a hydrogen atom;

in the form of a free base or of an addition salt with an acid.

25

Examples of compounds of the present invention are shown in table 1 hereinafter.
 However, the scope of the present invention is not limited by these compounds.
 The nomenclature is given according to IUPAC rules.

A further object of the present invention includes the group of compounds

of **table 1** of formula as defined hereunder:

1. *N*-(2-phenylethyl)-6-pyridin-4-ylpyrazin-2-amine 4-oxide
- 5 2. (+/-)-2-[(4-oxido-6-pyridin-4-ylpyrazin-2-yl)amino]-1-phenylethanol
3. (+/-)-6-2-[(6-chloro-4-oxidopyrazin-2-yl)amino]-1-phenylethanol
4. 6-chloro-*N*-(2-phenylethyl)pyrazin-2-amine 4-oxide

10


As a further object, the present invention concerns also methods for preparing the N-oxide pyrazine compounds represented by the aforementioned formula (I).

These compounds can be prepared, for example, according to methods explained below.

15

Preparation method

N-oxide pyrazine compounds represented by the aforementioned formula (I), may be prepared according to the method described in the scheme 1.



20

Scheme 1

(In the above scheme the definition of R₁, R₂, R₃, R₄, R₅ are the same as those already described for compound of formula (I)).

25

According to this method, the amine of formula (III), wherein R₅ and R₄ are

defined for compound of formula (I), is allowed to react with a compound of formula (II), at a suitable temperature ranging from 25° to 180°C under ordinary air to obtain a compound of formula(I).

When R1 represents a halogen atom, the compound of formula (I) is allowed to
5 react with a compound of formula (IV), wherein M represents a boronic acid or a stannyl group. The reaction may be carried out in the usual well known coupling reaction such as Suzuki or Stille reactions to afford the compound of formula (I).

10 Compounds of formula (II), (III) and (IV) are commercially available or may be synthesized according to well-known methods to one skilled in the art.

The compounds of the present invention have inhibitory activity against GSK3 β . Accordingly, the compounds of the present invention are useful as an active ingredient for the preparation of a medicament, which enables preventive and/or
15 therapeutic treatment of a disease caused by abnormal GSK3 β activity and more particularly of neurodegenerative diseases such as Alzheimer's disease. In addition, the compounds of the present invention are also useful as an active ingredient for the preparation of a medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Parkinson's disease,
20 tauopathies (e.g. Fronto temporal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy), Wilson's disease, Huntington's disease, Prion disease and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; amyotrophic lateral sclerosis,
25 peripheral neuropathies; retinopathies and glaucoma; and other diseases such as non-insulin dependent diabetes (such as diabetes type II) and obesity; malaria, manic depressive illness; schizophrenia; alopecia; cancers such as colorectal, prostate breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, several virus-induced tumours and in bone related pathologies;
30 parenchymal renal diseases or muscle atrophy. The medicament could also find an application in regenerative medicine. The medicament could also find an application in the treatment or prevention of *Pemphigus vulgaris*. The medicament could also find an application in the treatment of neutropenia induced by cancer

chemotherapy. The medicament could also find an application for therapeutic treatment of a disease characterized by cognitive and memory deficits such as in Alzheimer's disease, Parkinson disease, age associated memory impairment, mild cognitive impairment, brain trauma, schizophrenia and other conditions in which
5 such deficits are observed.

The present invention further relates to a method for treating neurodegenerative diseases caused by abnormal activity of GSK3 β and of the aforementioned diseases which comprises administering to a mammalian organism in need thereof an effective amount of a compound of the formula (I).
10

As the active ingredient of the medicament of the present invention, a substance may be used which is selected from the group consisting of the compound represented by the aforementioned formula (I) and pharmacologically acceptable salts thereof, and solvates thereof and hydrates thereof. The
15 substance, per se, may be administered as the medicament of the present invention; however, it is desirable to administer the medicament in a form of a pharmaceutical composition which comprises the aforementioned substance as an active ingredient and one or more pharmaceutical additives. As the active ingredient of the medicament of the present invention, two or more of the
20 aforementioned substances may be used in combination. The above pharmaceutical composition may be supplemented with an active ingredient of another medicament for the treatment of the above mentioned diseases. The type of pharmaceutical composition is not particularly limited, and the composition may be provided as any formulation for oral or parenteral administration. For example,
25 the pharmaceutical composition may be formulated, for example, in the form of pharmaceutical compositions for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, solutions and the like, or in the form of pharmaceutical compositions for parenteral administrations such as injections for intravenous, intramuscular, or subcutaneous
30 administration, drip infusions, transdermal preparations, transmucosal preparations, nasal drops, inhalants, suppositories and the like. Injections or drip infusions may be prepared as powdery preparations such as in the form of lyophilized preparations, and may be used by dissolving just before use in an

appropriate aqueous medium such as physiological saline. Sustained-release preparations such as those coated with a polymer may be directly administered intracerebrally.

5 Types of pharmaceutical additives used for the manufacture of the pharmaceutical composition, content ratios of the pharmaceutical additives relative to the active ingredient, and methods for preparing the pharmaceutical composition may be appropriately chosen by those skilled in the art. Inorganic or organic substances or solid or liquid substances may be used as pharmaceutical
10 additives. Generally, the pharmaceutical additives may be incorporated in a ratio ranging from 1% by weight to 90% by weight based on the weight of an active ingredient.

Examples of excipients used for the preparation of solid pharmaceutical
15 compositions include, for example, lactose, sucrose, starch, talc, cellulose, dextrin, kaolin, calcium carbonate and the like. For the preparation of liquid compositions for oral administration, a conventional inert diluent such as water or a vegetable oil may be used. The liquid composition may contain, in addition to the inert diluent, auxiliaries such as moistening agents, suspension aids,
20 sweeteners, aromatics, colorants, and preservatives. The liquid composition may be filled in capsules made of an absorbable material such as gelatin. Examples of solvents or suspension mediums used for the preparation of compositions for parenteral administration, e.g. injections, suppositories, include water, propylene glycol, polyethylene glycol, benzyl alcohol, ethyl oleate, lecithin and the like.
25 Examples of base materials used for suppositories include, for example, cacao butter, emulsified cacao butter, lauric lipid, witepsol.

The dose and frequency of administration of the medicament of the present invention are not particularly limited, and they may be appropriately chosen
30 depending on conditions such as a purpose of preventive and/or therapeutic treatment, a type of a disease, the body weight or age of a patient, severity of a disease and the like. Generally, a daily dose for oral administration to an adult may be 0.01 to 1,000 mg (the weight of an active ingredient), and the dose may

be administered once a day or several times a day as divided portions, or once in several days. When the medicament is used as an injection, administrations may preferably be performed continuously or intermittently in a daily dose of 0.001 to 100 mg (the weight of an active ingredient) to an adult.

5

Chemical Examples

Example 1 (Compound No. 4 of table 1)

6-Chloro-*N*-(2-phenylethyl)pyrazin-2-amine 4-oxide

10 A suspension of 0.330g (2.0 mmol) of 2,6-dichloro-pyrazine 4-oxide in 0.485g (4.0 mmol) of phenethylamine was allowed to stir under reflux for 10 mn.

Cooled water was added and the mixture extracted with dichloromethane, dried over sodium sulfate and evaporated to dryness.

15 The residue obtained was purified by chromatography on silica gel eluting with a mixture of dichloromethane/methanol/diethylamine in the proportions 97/3/0.3 to give after trituration with diethyl ether 0.370g (74%) of pure product as a grey solid.

Mp: 142-143°C

RMN ¹H (CDCl₃; 200 MHz) :

20 δ (ppm) : 7.50 (s, 1H), 7.30-7.10 (m, 5H), 5.10 (br s, 1H), 3.60 (dd, 2H), 2.90 (dd, 2H).

Example 2 (Compound No. 1 of table 1)

N-(2-phenylethyl)-6-pyridin-4-ylpyrazin-2-amine 4-oxide

25 A mixture containing 0.250g (1.0 mmol) of 6-chloro-*N*-(2-phenylethyl)pyrazin-2-amine 4-oxide, 0.296g (2.40 mmol) of 4-pyridine boronic acid, 0.60mL (1.2 mmol) of a 2M solution of sodium carbonate in water and 0.116g (0.1 mmol) of tetrakis(triphenylphosphine)palladium (0) in 5 mL of a mixture of ethanol/water in the proportions 5/1 was stirred under reflux for 16h. Cooled water was added and
30 the mixture extracted with dichloromethane, dried over sodium sulfate and evaporated to dryness. The residue obtained was purified by chromatography on silica gel eluting with a mixture of dichloromethane/methanol/diethylamine in the proportions 98/2/0.2 to give after trituration with diethyl ether 0.058g (20%) of pure

product as a yellow solid.

Mp: 184-185°C

RMN ¹H (CDCl₃; 200 MHz) :

δ (ppm) : 8.70 (d, 2H); 7.90 (s, 1H); 7.70 (d, 2H); 7.45 (s, 1H); 7.30-7.00 (m, 5H);
5 4.80 (br t, 1H), 3.70 (m, 2H); 2.90 (t, 2H).

A list of chemical structures and physical data for compounds of the aforementioned formula (I), illustrating the present invention, is given in table 1.

The compounds have been prepared according to the methods of the examples.

10 In the table, (Rot.) indicates the levorotatory or dextrorotatory properties of the enantiomeric compound.






Table 1

15

No.	Rot	R5 N R4	R1	R3	R2	Mp °C	salt
1				H	H	184-185	Free base
2	(+/-)			H	H	224-225	Free base
3	(+/-)		Cl	H	H	175-176	Free base

No.	Rot		R1	R3	R2	Mp °C	salt
4			Cl	H	H	142-143	Free base

Test Example: Inhibitory activity of the medicament of the present invention against GSK3β:

Four different protocols can be used.

5 In a first protocol : 7.5 μM of prephosphorylated GS1 peptide and 10 μM ATP (containing 300,000 cpm of ³³P-ATP) were incubated in 25 mM Tris-HCl, pH 7.5, 0.6 mM DTT, 6 mM MgCl₂, 0.6 mM EGTA, 0.05 mg/ml BSA buffer for 1 hour at room temperature in the presence of GSK3beta (total reaction volume : 100 microliters).

10

In a second protocol : 4.1 μM of prephosphorylated GS1 peptide and 42 μM ATP (containing 260,000 cpm ³³P-ATP) were incubated in 80 mM Mes-NaOH, pH 6.5, 1 mM Mg acetate, 0.5 mM EGTA, 5 mM 2-mercaptoethanol, 0.02% Tween 20, 10% glycerol buffer for 2 hours at room temperature in the presence of GSK3beta.

15

In a third protocol : 7.5 μM of prephosphorylated GS1 peptide and 10 μM ATP (containing 300,000 cpm of ³³P-ATP) were incubated in 50 mM Hepes, pH 7.2, 1 mM DTT, 1 mM MgCl₂, 1 mM EGTA, 0.01% Tween 20 buffer for one hour at room temperature in the presence of GSK3beta (total reaction volume : 100 microliters).

20

In a fourth protocol : 7.5 μM of prephosphorylated GS1 peptide and 10 μM ATP (containing 300,000 cpm of ³³P-ATP) were incubated in 50 mM Hepes, pH 7.2, 1 mM DTT, 1 mM MgCl₂, 1 mM EGTA, 0.01% Tween 20 buffer for 90 minutes at room temperature in the presence of commercial GSK3beta (Millipore) (total reaction volume : 100 microliters).

25

Inhibitors were solubilised in DMSO (final solvent concentration in the reaction medium, 1%).

The reaction was stopped with 100 microliters of a solution made of 25 g polyphosphoric acid (85% P₂O₅), 126 ml 85% H₃PO₄, H₂O to 500 ml and then diluted to 1:100 before use. An aliquot of the reaction mixture was then transferred to Whatman P81 cation exchange filters and rinsed with the solution
 5 described above. Incorporated ³³P radioactivity was determined by liquid scintillation spectrometry.

The phosphorylated GS-1 peptide had the following sequence:

NH₂-YRRAAVPPSPSLSRHSSPHQS(P)EDEE-COOH. (Woodgett, J. R. (1989) Analytical Biochemistry 180, 237-241.

10

The GSK3 β inhibitory activity of the compounds of the present invention are expressed in IC₅₀, and as an illustration the range of IC₅₀'s of the compounds in table 1 are between 0.1 nanomolar to 3 micromolar concentrations.

15 For example, on the protocol 3, the compound No. 2 of table 1 shows an IC₅₀ of 0.506 μ M.

Formulation Example

(1) Tablets

20 The ingredients below were mixed by an ordinary method and compressed by using a conventional apparatus.

Compound of Example 1	30 mg
Crystalline cellulose	60 mg
Corn starch	100 mg
25 Lactose	200 mg
Magnesium stearate	4 mg

(2) Soft capsules

30 The ingredients below were mixed by an ordinary method and filled in soft capsules.

Compound of Example 1	30 mg
Olive oil	300 mg
Lecithin	20 mg

(3) Parenteral preparations

The ingredients below were mixed by an ordinary method to prepare injections contained in a 1 ml ampoule.


5	Compound of Example 1	3 mg
	Sodium chloride	4 mg
	Distilled water for injection	1 ml

Industrial Applicability

- 10 The compounds of the present invention have GSK3 β inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activity of GSK3 β and more particularly of neurodegenerative diseases.

What is claimed is:

1. A N-oxide pyrazine derivative represented by formula (I) or a salt thereof:



5 wherein:

R1 represents a 4-pyridine ring, a halogen atom;

R2 represents a hydrogen atom;

R3 represents a hydrogen atom;

R4 represents:


10 - a phenylC₁₋₃alkyl group, this group being optionally substituted by 1 to 4 substituents selected from a C₁₋₆ alkyl group, a halogen atom, a C₁₋₂ perhalogenated alkyl group, a C₁₋₃ halogenated alkyl group, a hydroxyl group, a C₁₋₆ alkoxy group, a C₁₋₂ perhalogenated alkoxy group, a C₁₋₆ alkylsulfonyl group, a nitro, a cyano, an amino, a C₁₋₆ monoalkylamino group or a C₂₋₁₂ dialkylamino group, an acetoxy group, an aminosulfonyl group;

15

R5 represents a hydrogen atom;

in the form of a free base or of an addition salt with an acid.

2. A N-oxide pyrazine derivative or a salt thereof :



20

wherein:

R1 represents a 4-pyridine ring, a halogen atom;

R2 represents a hydrogen atom;

R3 represents a hydrogen atom;

25 R4 represents: a phenylC₁₋₃alkyl group, this group being optionally substituted by

1 to 4 substituents selected from a halogen atom, a hydroxyl group;
R5 represents a hydrogen atom;
in the form of a free base or of an addition salt with an acid.

5 3. A N-oxide pyrazine derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1 and 2 which is selected from the group consisting of :

- *N*-(2-phenylethyl)-6-pyridin-4-ylpyrazin-2-amine 4-oxide
- (+/-)2-[(4-oxido-6-pyridin-4-ylpyrazin-2-yl)amino]-1-phenylethanol
- 10 • (+/-)6-2-[(6-chloro-4-oxidopyrazin-2-yl)amino]-1-phenylethanol
- 6-chloro-*N*-(2-phenylethyl)pyrazin-2-amine 4-oxide

4. A medicament comprising as an active ingredient a substance selected from the group consisting of N-oxide pyrazine derivative represented by formula
15 (I) or salts thereof, or a solvate thereof or a hydrate thereof according to claim 1 to 3.

5. A GSK3 β inhibitor selected from the group of a N-oxide pyrazine derivative represented by formula (I) or salts thereof, or a solvate thereof or a
20 hydrate thereof according to claim 1.

6. Compound according to claims 1 to 3 for preventive and/or therapeutic treatment of a disease caused by abnormal GSK3 β activity.

25 7. Compound according to claims 1 to 3 for preventive and/or therapeutic treatment of a neurodegenerative disease.

8. Compound according to claim 1 to 3, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, tauopathies, vascular dementia; acute stroke, traumatic injuries; cerebrovascular accidents, brain cord trauma, spinal cord trauma; peripheral neuropathies; retinopathies or glaucoma.
30

9. Compound according to claims 1 to 3 for preventive and/or therapeutic treatment of non-insulin dependent diabetes; obesity; manic depressive illness; schizophrenia; alopecia; cancers; parenchymal renal diseases or muscle atrophy.
- 5 10. Compound according to claim 9 wherein cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia or virus-induced tumors.
- 10 11. Compound according to claims 1 to 3 for preventive and/or therapeutic treatment of malaria.
12. Compound according to claims 1 to 3 for preventive and/or therapeutic treatment of bone diseases.
- 15 13. Compound according to claims 1 to 3 for preventive and/or therapeutic treatment of Pemphigus vulgaris.
14. Compound according to claims 1 to 3 for preventive and/or therapeutic treatment of neutropenia induced by cancer chemotherapy.
- 20 15. Compound according to claims 1 to 3 for therapeutic treatment of a disease characterized by cognitive and memory deficits.

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2009/006445

A. CLASSIFICATION OF SUBJECT MATTER
 INV. C07D241/52 C07D401/04 A61K31/497 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2004/055005 A (ASTRAZENECA AB [SE]; BERG STEFAN [SE]; HELLBERG SVEN [SE]; SOEDERMAN P) 1 July 2004 (2004-07-01) the whole document -----	1-15

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

21 October 2009

Date of mailing of the international search report

27/10/2009

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040,
 Fax: (+31-70) 340-3016

Authorized officer

Lauro, Paola

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/IB2009/006445
--

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2004055005 A	01-07-2004	AU 2003287135 A1 BR 0317294 A CA 2508042 A1 CN 1729185 A EP 1575938 A1 JP 2006513180 T KR 20050084363 A MX PA05006243 A NZ 540449 A US 2006116362 A1 ZA 200504617 A	09-07-2004 08-11-2005 01-07-2004 01-02-2006 21-09-2005 20-04-2006 26-08-2005 19-08-2005 29-02-2008 01-06-2006 29-03-2006
